AI-generated analysis. Always verify with the original filing.
On March 12, 2026, Amphastar Pharmaceuticals, Inc.’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, expected to continue for an indefinite period. The primary goal is to offset dilution created by the Company’s equity compensation programs, with purchases through open market, Rule 10b5-1 plans, or other means compliant with SEC requirements.
Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events On March 12, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expected
Buyback Auth.
$50 million increase